|
1-(3-chlorophenyl)-3-[(3,4,5-trimethoxybenzoyl)amino]urea |
|
Acinetobacter |
Biofilm |
Preclinical (in vitro) |
Sambanthamoorthy K, et al. 2015. Bioorg Med Chem Lett |
|
1-(4-chlorophenyl)-3-[3-(trifluoromethyl)phenyl]urea |
Depiction based on curated SMILES
F
F
F
Cl
NH
O
N
H
|
Bacillus |
Nutritional/Metabolic factor |
Preclinical (in vitro) |
Fernandes AS, et al. 2021. Front Microbiol |
|
1-[[5-tert-butyl-2-[(4-fluorophenyl)methyl]pyrazole-3-carbonyl]amino]-3-phenylurea |
Depiction based on curated SMILES
HN
O
N
H
HN
O
CH
3
F
N
N
H
3
C
H
3
C
|
Mycobacterium |
Motility |
Preclinical (in vitro) |
Ouertatani-Sakouhi H, et al. 2017. PLoS One |
|
1-Phenyl-3-(1,2,3-thiadiazol-5-yl)urea |
Depiction based on curated SMILES
O
NH
N
H
N
N
S
|
Shigella |
VirF |
Preclinical (in vitro) |
Hurt JK, et al. 2010. J Biomol Screen; Emanuele AA, et al. 2014. J Antibiot (Tokyo); Emanuele AA, et al. 2015. PLoS One |
|
Imidocarb |
Depiction based on curated SMILES
O
NH
N
NH
N
H
NH
N
|
Escherichia Yersinia |
TTSS (Type III secretion system) TTSS (Type III secretion system) |
Preclinical (in vitro) Preclinical (in vitro) |
Pan NJ, et al. 2009. Antimicrob Agents Chemother
|
|
N-(1,3-dimethyl-2-oxo-6-pyrrolidin-1-yl-2,3-dihydro-1H-benzimidazol-5-yl)-N'-(3,4-dimethylphenyl)urea |
Depiction based on curated SMILES
CH
3
CH
3
N
O
H
3
C
N
N
CH
3
N
H
O
N
H
|
Yersinia |
TTSS (Type III secretion system) |
Preclinical (in vitro) |
Harmon DE, et al. 2010. Antimicrob Agents Chemother |
|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |